Dabigatran etexilate is an oral anticoagulant medication, marketed as Pradaxa. It is a direct thrombin inhibitor, meaning it blocks the activity of thrombin, a key enzyme in the blood clotting process [1]. This action reduces the formation of blood clots [1].
What is Dabigatran Etexilate Used For?
Dabigatran etexilate is prescribed to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation [1]. It is also used to treat venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent recurrence of VTE [1]. Additionally, it is used to prevent blood clots in patients who have undergone hip or knee replacement surgery [1].
How Does Dabigatran Etexilate Work?
Dabigatran etexilate functions as a prodrug, meaning it is inactive until it is converted into its active form, dabigatran, in the body [1]. Dabigatran directly inhibits both free and clot-bound thrombin. Thrombin is essential for converting fibrinogen to fibrin, a critical step in clot formation. By inhibiting thrombin, dabigatran etexilate prevents the formation and growth of blood clots [1].
When Does Dabigatran Etexilate Patent Exclusivity Expire?
Information on the specific patent expiry dates for dabigatran etexilate and its formulations can be found through resources like DrugPatentWatch.com [2]. Patent exclusivity periods are crucial for determining when generic versions of a drug may become available.
What Are the Risks Associated with Dabigatran Etexilate?
The primary risk associated with dabigatran etexilate is bleeding, which can range from minor to severe and potentially life-threatening [1]. Other side effects may include indigestion, stomach pain, nausea, and an increased risk of certain gastrointestinal issues [1].
Can Biosimilars of Dabigatran Etexilate Be Developed?
Dabigatran etexilate is a small molecule drug, not a biologic. Therefore, the concept of "biosimilars" as applied to biologic drugs does not directly apply. Instead, generic versions of dabigatran etexilate, which are chemically identical copies, can be developed and approved once patent exclusivity and any other market protections expire [2].
What Are the Alternatives to Dabigatran Etexilate?
Alternative anticoagulant medications include warfarin, a vitamin K antagonist, and other direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, and edoxaban [3]. The choice of anticoagulant depends on individual patient factors, including their medical history, other medications, and specific condition being treated [3].
How is Dabigatran Etexilate Priced?
The pricing of dabigatran etexilate, as with most prescription medications, can vary significantly based on factors such as insurance coverage, pharmacy, location, and whether a generic version is available [4].
Who Manufactures Dabigatran Etexilate?
Dabigatran etexilate is manufactured and marketed by Boehringer Ingelheim under the brand name Pradaxa [5].
*
**Sources:
[1] https://www.fda.gov/media/78223/download
[2] https://drugpatentwatch.com/
[3] https://www.nhs.uk/conditions/blood-clots/treatment/
[4] https://www.goodrx.com/pradaxa
[5] https://www.boehringer-ingelheim.com/us/products-therapies/cardiovascular-diseases/pradaxa